Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Newborn | 39 | 2024 | 1479 | 1.750 |
Why?
|
| Cardiopulmonary Resuscitation | 7 | 2024 | 25 | 1.520 |
Why?
|
| Sepsis | 6 | 2023 | 102 | 1.490 |
Why?
|
| Hypothermia, Induced | 4 | 2024 | 17 | 1.430 |
Why?
|
| Hypoxia-Ischemia, Brain | 4 | 2024 | 21 | 1.430 |
Why?
|
| Emergency Medical Services | 7 | 2024 | 29 | 1.330 |
Why?
|
| Streptococcal Infections | 5 | 2020 | 184 | 1.110 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 5 | 2023 | 10 | 1.070 |
Why?
|
| Streptococcus agalactiae | 5 | 2020 | 202 | 1.020 |
Why?
|
| Infant | 21 | 2024 | 2244 | 0.840 |
Why?
|
| Asphyxia Neonatorum | 1 | 2023 | 11 | 0.830 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 4 | 0.780 |
Why?
|
| Delivery Rooms | 1 | 2021 | 3 | 0.780 |
Why?
|
| Humans | 41 | 2024 | 14537 | 0.760 |
Why?
|
| Meningitis, Bacterial | 2 | 2020 | 38 | 0.730 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 293 | 0.610 |
Why?
|
| Neonatal Sepsis | 3 | 2023 | 29 | 0.570 |
Why?
|
| Infant, Newborn, Diseases | 4 | 2022 | 73 | 0.570 |
Why?
|
| Consensus | 7 | 2024 | 62 | 0.560 |
Why?
|
| Female | 21 | 2024 | 9103 | 0.500 |
Why?
|
| Infant, Premature, Diseases | 2 | 2023 | 19 | 0.490 |
Why?
|
| Tertiary Care Centers | 4 | 2023 | 80 | 0.470 |
Why?
|
| Disease Outbreaks | 3 | 2023 | 111 | 0.460 |
Why?
|
| South Africa | 18 | 2024 | 7596 | 0.460 |
Why?
|
| Child | 13 | 2024 | 2242 | 0.430 |
Why?
|
| Premature Birth | 2 | 2023 | 80 | 0.400 |
Why?
|
| First Aid | 7 | 2024 | 8 | 0.390 |
Why?
|
| Pregnancy | 9 | 2023 | 1862 | 0.380 |
Why?
|
| Prospective Studies | 7 | 2024 | 1160 | 0.350 |
Why?
|
| Male | 13 | 2024 | 6754 | 0.330 |
Why?
|
| Thienamycins | 1 | 2009 | 6 | 0.330 |
Why?
|
| Klebsiella Infections | 1 | 2009 | 13 | 0.320 |
Why?
|
| Cross Infection | 3 | 2024 | 52 | 0.320 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 14 | 0.300 |
Why?
|
| Risk Factors | 5 | 2024 | 1475 | 0.280 |
Why?
|
| Gestational Age | 3 | 2023 | 80 | 0.280 |
Why?
|
| Hydrops Fetalis | 1 | 2006 | 3 | 0.280 |
Why?
|
| Parvoviridae Infections | 1 | 2006 | 4 | 0.280 |
Why?
|
| Peritonitis | 1 | 2006 | 5 | 0.280 |
Why?
|
| Parvovirus B19, Human | 1 | 2006 | 5 | 0.280 |
Why?
|
| Anti-Infective Agents | 2 | 2024 | 57 | 0.270 |
Why?
|
| Case-Control Studies | 4 | 2020 | 480 | 0.260 |
Why?
|
| Child, Hospitalized | 2 | 2024 | 26 | 0.250 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 6 | 0.230 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 14 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2023 | 799 | 0.220 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 4 | 0.220 |
Why?
|
| Pulmonary Surfactants | 1 | 2023 | 8 | 0.220 |
Why?
|
| Hypothermia | 1 | 2023 | 3 | 0.220 |
Why?
|
| Lopinavir | 1 | 2024 | 137 | 0.210 |
Why?
|
| Maternal Death | 1 | 2023 | 25 | 0.210 |
Why?
|
| Ritonavir | 1 | 2024 | 137 | 0.210 |
Why?
|
| HIV Protease Inhibitors | 1 | 2024 | 92 | 0.210 |
Why?
|
| Asphyxia | 1 | 2023 | 5 | 0.210 |
Why?
|
| Meningitis | 1 | 2023 | 26 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 54 | 0.210 |
Why?
|
| Communicable Diseases | 1 | 2023 | 62 | 0.200 |
Why?
|
| Neuroprotection | 1 | 2022 | 4 | 0.200 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2021 | 5 | 0.190 |
Why?
|
| Brain Diseases | 1 | 2022 | 24 | 0.190 |
Why?
|
| Brain | 1 | 2022 | 53 | 0.190 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 6 | 0.190 |
Why?
|
| Listeriosis | 1 | 2021 | 8 | 0.190 |
Why?
|
| Candidemia | 1 | 2021 | 13 | 0.190 |
Why?
|
| HIV Infections | 4 | 2023 | 5097 | 0.190 |
Why?
|
| Candida | 1 | 2021 | 24 | 0.180 |
Why?
|
| Growth and Development | 1 | 2020 | 4 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 24 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 23 | 0.180 |
Why?
|
| Infant, Premature | 3 | 2023 | 56 | 0.180 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 3 | 0.170 |
Why?
|
| Deoxycholic Acid | 1 | 2020 | 2 | 0.170 |
Why?
|
| Milk, Human | 1 | 2020 | 23 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2024 | 1748 | 0.170 |
Why?
|
| Amphotericin B | 1 | 2020 | 10 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2020 | 40 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1422 | 0.160 |
Why?
|
| Adolescent | 5 | 2024 | 2985 | 0.160 |
Why?
|
| Developing Countries | 1 | 2021 | 400 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2023 | 967 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 22 | 0.140 |
Why?
|
| Infant Mortality | 3 | 2023 | 97 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.140 |
Why?
|
| Prevalence | 3 | 2024 | 1192 | 0.130 |
Why?
|
| Adult | 5 | 2023 | 5913 | 0.120 |
Why?
|
| Advisory Committees | 2 | 2024 | 14 | 0.120 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 9 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 43 | 0.110 |
Why?
|
| Hospitals | 2 | 2023 | 103 | 0.100 |
Why?
|
| Emergency Treatment | 2 | 2023 | 13 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 1324 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 96 | 0.090 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 56 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 91 | 0.090 |
Why?
|
| Stillbirth | 2 | 2023 | 83 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2023 | 16 | 0.090 |
Why?
|
| Blood Culture | 2 | 2021 | 11 | 0.090 |
Why?
|
| Piperacillin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 7 | 0.080 |
Why?
|
| Klebsiella | 1 | 2009 | 6 | 0.080 |
Why?
|
| Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
|
| beta-Lactam Resistance | 1 | 2009 | 5 | 0.080 |
Why?
|
| beta-Lactamases | 1 | 2009 | 23 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 133 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 156 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2009 | 149 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2006 | 21 | 0.070 |
Why?
|
| Calcinosis | 1 | 2006 | 11 | 0.070 |
Why?
|
| Meconium | 1 | 2006 | 20 | 0.070 |
Why?
|
| Radiography | 1 | 2006 | 80 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 685 | 0.070 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2024 | 3 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 18 | 0.060 |
Why?
|
| Dyspnea | 1 | 2023 | 10 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2023 | 13 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 127 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 385 | 0.050 |
Why?
|
| Resuscitation | 1 | 2023 | 18 | 0.050 |
Why?
|
| Age Factors | 1 | 2024 | 370 | 0.050 |
Why?
|
| Carbapenems | 1 | 2023 | 17 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2023 | 87 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 260 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 244 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2024 | 187 | 0.050 |
Why?
|
| Head | 1 | 2022 | 8 | 0.050 |
Why?
|
| Meningitis, Listeria | 1 | 2021 | 3 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2021 | 29 | 0.050 |
Why?
|
| Candida tropicalis | 1 | 2021 | 2 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hospitalization | 1 | 2024 | 418 | 0.050 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.050 |
Why?
|
| Candida parapsilosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 21 | 0.050 |
Why?
|
| Drug Resistance, Fungal | 1 | 2021 | 13 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2021 | 22 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 47 | 0.050 |
Why?
|
| Candida albicans | 1 | 2021 | 15 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2021 | 45 | 0.050 |
Why?
|
| Birth Weight | 1 | 2021 | 80 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 563 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2020 | 77 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 239 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 42 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 195 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 81 | 0.040 |
Why?
|
| Perinatal Death | 1 | 2019 | 33 | 0.040 |
Why?
|
| Ureaplasma | 1 | 2019 | 4 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 32 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 272 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 140 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 153 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 551 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.030 |
Why?
|
| Animals | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 193 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2498 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 325 | 0.030 |
Why?
|
| HIV | 1 | 2015 | 380 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 51 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 188 | 0.020 |
Why?
|